Nestle Health Science SA has entered into a strategic collaboration with Netherlands-based Caelus Health to develop microbiome-based food supplements for the prevention and early treatment of cardio-metabolic diseases.
Under the terms of a global development and option agreement signed by both firms, Nestlé has agreed to fund Caelus’ efforts to further pursue the preclinical and clinical development of its lead microbiome-based products
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?